Aristotle further discerned two modes of causation: proper (prior) causation and accidental (chance) causation. All causes, proper and accidental, can be spoken as potential or as actual, particular or generic. The same language refers to the effects of causes, so that generic effects are assigned to generic causes, particular effects to particular causes, and actual effects to operating causes. Averting infinite regress, Aristotle inferred the first mover—an unmoved mover. The first movers motion, too, must have been caused, but, being an unmoved mover, must have moved only toward a particular goal or desire. Pyrrhonism
While the plausibility of causality was accepted in Pyrrhonism, it was equally accepted that it was plausible that nothing was the cause of anything. Middle Ages
In line with Aristotelian cosmology, Thomas Aquinas posed a hierarchy prioritizing Aristotles four causes: "final > efficient > material > formal". Aquinas sought to identify the first efficient cause—now simply first cause—as everyone would agree, said Aquinas, to call it God. Later in the Middle Ages, many scholars conceded that the first cause was God, but explained that many earthly events occur within Gods design or plan, and thereby scholars sought freedom to investigate the numerous secondary causes. After the Middle Ages
For Aristotelian philosophy before Aquinas, the word cause had a broad meaning. It meant answer to a why question or explanation, and Aristotelian scholars recognized four kinds of such answers. With the end of the Middle Ages, in many philosophical usages, the meaning of the word cause narrowed.
Frovatriptan, sold under the brand name Frova, is a triptan drug developed by Vernalis for the treatment of migraine headaches and for short term prevention of menstrual migraine. The product is licensed to Endo Pharmaceuticals in North America and Menarini in Europe. Medical uses
Frovatriptan is used in the treatment of migraine. Available forms
It is available as 2.5 mg tablets. Contraindications
Frovatriptan should not be given to patients with:

Ischemic heart disease
Cerebrovascular syndrome
Peripheral vascular disease
Uncontrolled hypertension
Hemiplegic or basilar migraine

Side effects
Rare, but serious cardiac events have been reported in patients with risk factors predictive of CAD. These include: coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia and ventricular fibrillation. Pharmacology
Pharmacodynamics
Frovatriptan is a serotonin receptor agonist, with high affinity for the 5-HT1B/1D receptors. It has no significant effects on the GABAA mediated channel activity and benzodiazepine binding sites. Frovatriptan inhibits excessive dilation of arteries that supply blood to the head. Pharmacokinetics
Frovatriptan has a terminal elimination half-life of approximately 26 hours, making it the longest within its class. Society and culture
US licensing
Frovatriptan is available only by prescription in the United States and Canada, where a secondary New Drug Approval (sNDA) was filed in July 2006. References
External links
Frova (manufacturers website)
Frovatriptan Succinate  (patient information)
FDA labeling